Radiolabeled Metaiodobenzylguanidine for the Treatment of Neuroblastoma

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2008 Dec 4

PMID 18707633

Citations 39

Authors

Steven G Dubois

Katherine K Matthay

Affiliations

Soon will be listed here.

Abstract

Introduction: Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors.

Methods: The available English language literature was reviewed for original research investigating in vitro, in vivo and clinical applications of radiolabeled MIBG for neuroblastoma.

Results: MIBG is actively transported into neuroblastoma cells by the norepinephrine transporter. Preclinical studies demonstrate substantial activity of radiolabeled MIBG in neuroblastoma models, with (131)I-MIBG showing enhanced activity in larger tumors compared to (125)I-MIBG. Clinical studies of (131)I-MIBG in patients with relapsed or refractory neuroblastoma have identified myelosuppression as the main dose-limiting toxicity, necessitating stem cell reinfusion at higher doses. Most studies report a response rate of 30-40% with (131)I-MIBG in this population. More recent studies have focused on the use of (131)I-MIBG in combination with chemotherapy or myeloablative regimens.

Conclusions: (131)I-MIBG is an active agent for the treatment of patients with neuroblastoma. Future studies will need to define the optimal role of this targeted radiopharmaceutical in the therapy of this disease.

Citing Articles

Recent advances in the development of Ac- and At-labeled radioligands for radiotheranostics.

Munekane M, Fuchigami T, Ogawa K Anal Sci. 2024; 40(5):803-826.

PMID: 38564087 PMC: 11035452. DOI: 10.1007/s44211-024-00514-w.

Biodistribution and radiation dosimetry of I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models.

Moraitis A, Jentzen W, Reiter G, Schmitz J, Poppel T, Weber M EJNMMI Phys. 2024; 11(1):3.

PMID: 38167953 PMC: 10761661. DOI: 10.1186/s40658-023-00604-0.

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.

Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.

PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J Clin Cancer Res. 2022; 28(18):4146-4157.

PMID: 35861867 PMC: 9475242. DOI: 10.1158/1078-0432.CCR-22-0400.

Development of FeO core-TiO shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization.

Liu W, Mirzoeva S, Yuan Y, Deng J, Chen S, Lai B Cancer Nanotechnol. 2021; 12(1):12.

PMID: 34777621 PMC: 8550682. DOI: 10.1186/s12645-021-00081-z.

References

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

Lashford L, Moyes J, Ott R, Fielding S, Babich J, Mellors S . The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma. Eur J Nucl Med. 1988; 13(11):574-7. DOI: 10.1007/BF02574771. View

de Kraker J, Hoefnagel C, Caron H, Valdes Olmos R, Zsiros J, Heij H . First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 1995; 31A(4):600-2. DOI: 10.1016/0959-8049(95)00063-o. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Dubois S, Messina J, Maris J, Huberty J, Glidden D, Veatch J . Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004; 22(12):2452-60. DOI: 10.1200/JCO.2004.08.058. View

van Santen H, de Kraker J, van Eck B, de Vijlder J, Vulsma T . Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer. 2003; 98(2):389-96. DOI: 10.1002/cncr.11523. View

Mastrangelo R, Tornesello A, Lasorella A, Iavarone A, Mastrangelo S, Riccardi R . Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol. 1997; 31(1-2):153-8. DOI: 10.1023/a:1005770405844. View

Kang T, Brophy P, Hickeson M, Heyman S, Evans A, Charron M . Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol. 2003; 25(10):769-73. DOI: 10.1097/00043426-200310000-00005. View

Lashford L, Lewis I, Fielding S, Flower M, Meller S, Kemshead J . Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992; 10(12):1889-96. DOI: 10.1200/JCO.1992.10.12.1889. View

10.

Gaze M, Wheldon T, ODonoghue J, Hilditch T, McNee S, Simpson E . Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer. 1995; 31A(2):252-6. DOI: 10.1016/0959-8049(94)e0036-4. View

11.

Montaldo P, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M . Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer. 1996; 67(1):95-100. DOI: 10.1002/(SICI)1097-0215(19960703)67:1<95::AID-IJC16>3.0.CO;2-B. View

12.

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

13.

Brans B, Laureys G, Schelfhout V, Wiele C, Potter C, Dhooge C . Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. Eur J Nucl Med. 1998; 25(2):144-9. DOI: 10.1007/s002590050207. View

14.

Gaze M, Huxham I, Mairs R, Barrett A . Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer. 1991; 47(6):875-80. DOI: 10.1002/ijc.2910470615. View

15.

Mairs R, Russell J, Cunningham S, ODonoghue J, Gaze M, Owens J . Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer. 1995; 31A(4):576-81. DOI: 10.1016/0959-8049(95)00052-k. View

16.

Garaventa A, Bellagamba O, Lo Piccolo M, Milanaccio C, Lanino E, Bertolazzi L . 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer. 1999; 81(8):1378-84. PMC: 2362971. DOI: 10.1038/sj.bjc.6694223. View

17.

Dubois S, Kalika Y, Lukens J, Brodeur G, Seeger R, Atkinson J . Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999; 21(3):181-9. DOI: 10.1097/00043426-199905000-00005. View

18.

Parisi M, Matthay K, Huberty J, Hattner R . Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology. 1992; 184(2):463-7. DOI: 10.1148/radiology.184.2.1620849. View

19.

Smets L, Loesberg C, Janssen M, Metwally E, Huiskamp R . Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989; 49(11):2941-4. View

20.

Cunningham S, Boyd M, Brown M, Carlin S, McCluskey A, Livingstone A . A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol. 2000; 35(6):708-11. DOI: 10.1002/1096-911x(20001201)35:6<708::aid-mpo49>3.0.co;2-f. View